Halogenated Hydrocarbon Doai Patents (Class 514/743)
  • Patent number: 10076441
    Abstract: A method for cerebral cooling is described using a cooling assembly, which includes first and second elongate tubular members adapted for insertion into a nasal cavity of a patient through the patient's nostrils. The elongate tubular members each have a proximal end, a distal end, a lumen extending therebetween, and a plurality of ports in fluid communication with the lumen. The cooling assembly also includes a manifold and a reservoir, which contains a pressurized fluid that includes a propellant having a boiling point less than 22° C. The elongate tubular members are inserted into the nasal cavity through the patient's nostrils and pressurized fluid is delivered onto a surface of the nasal cavity by infusing the pressurized fluid from the reservoir through the manifold, into the lumens and through the plurality of ports of the first and second elongate tubular members.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: September 18, 2018
    Assignee: BrainCool AB
    Inventors: Allan Rozenberg, John K Hoffman, James D Savage
  • Patent number: 9757460
    Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: September 12, 2017
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
  • Publication number: 20140329912
    Abstract: Compositions and methods for contraception are disclosed that use 1-bromopropane.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 6, 2014
    Applicant: INTEGRITY PHARMACEUTICALS, LLC
    Inventor: James A. Barron
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Patent number: 8703829
    Abstract: The invention provides compounds of Formula (I): R1?R2??(I) wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 22, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Gerald B. Hammond, Bo Xu, Paula J. Bates
  • Patent number: 8642531
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: February 4, 2014
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8513309
    Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Oxygen Biotherapeutics, Inc.
    Inventor: Gerald Klein
  • Patent number: 8337824
    Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
    Type: Grant
    Filed: August 22, 2009
    Date of Patent: December 25, 2012
    Assignee: Relypsa, Inc.
    Inventors: Detlef Albrecht, Michael Burdick, Han-Ting Chang, Dominique Charmot, Ramakrishnan Chidambaram, Eric Connor, Sherin Halfon, I-Zu Huang, Mingjun Liu, Jonathan Mills, Werner Strüver
  • Publication number: 20120213832
    Abstract: A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A?) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A?) is represented by [a?] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70?(a)?99.99, 0.01?(b)?5 30, 1?[a?]/5+(c)/1, 0?[a?]?95, and 0?(c)?250.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 23, 2012
    Inventors: Tatsuya Ori, Haruka Nishitani, Sayuri Iwasaki, Yuya Yamamoto, Chidzuru Nishimoto
  • Patent number: 8222300
    Abstract: The present invention provides methods of using halogenated volatile compounds, e.g., halogenated ether, for treating a neurological disorder, e.g., Parkinson's disease.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: July 17, 2012
    Assignee: Mouse Specifics, Inc.
    Inventor: Thomas G. Hampton
  • Publication number: 20120171281
    Abstract: The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site.
    Type: Application
    Filed: May 5, 2010
    Publication date: July 5, 2012
    Inventors: Danguole Spakevicius, Hatice Ozsoy
  • Publication number: 20120083510
    Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 5, 2012
    Inventor: Gerald Klein
  • Patent number: 8053478
    Abstract: Disclosed are diaryl iodonium compositions with antimicrobial activity and low toxicity to plants and mammals. The present diaryl iodonium compositions include a tri-substituted aryl group and a heteroaryl group which produce substantially no chlorobenzene and/or 1,2-dichlorobenzene when applied to microbes.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: November 8, 2011
    Assignee: Cornell Development Group, LLC
    Inventors: Leonard H. Wojcik, Jr., David D. Cornell
  • Publication number: 20110252694
    Abstract: Soil fumigation compositions are provided herein that include methyl iodide, at least one fluorocarbon or hydrofluorocarbon, at least one surfactant, and water. The fumigant can be produced by combining the water and surfactant with an initial mixture that is an azeotropic or azeotrope-like mixture of methyl iodide and at least one fluorocarbon or hydrofluorocarbon. The fumigant compositions can be utilized in drip fumigation processes, and have increased volatility as compared to methyl iodide alone, which can reduce the risk of water contamination when utilizing methyl iodide as a fumigant.
    Type: Application
    Filed: April 19, 2010
    Publication date: October 20, 2011
    Applicant: HONEYWELL INTERNATIONAL, INC.
    Inventors: Andrew Joseph Poss, Rajiv Ratna Singh, David Nalewajek, Cheryl Cantlon
  • Patent number: 7999011
    Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: August 16, 2011
    Assignee: Baxter International Inc.
    Inventors: Raul Trillo, Ralph A. Lessor, Satish Pejaver, Navneet Puri
  • Patent number: 7939515
    Abstract: Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: May 10, 2011
    Assignee: Galderma S.A.
    Inventor: Ivonne Arellano Mendoza
  • Patent number: 7812058
    Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: October 12, 2010
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Maurizio Pellecchia
  • Patent number: 7767232
    Abstract: Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: August 3, 2010
    Assignee: New York University
    Inventors: Evgeny Nudler, Ruslan Rafikova, Olga Rafikova
  • Publication number: 20100184727
    Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.
    Type: Application
    Filed: June 7, 2007
    Publication date: July 22, 2010
    Applicant: SUMMIT (CAMBRIDGE) LIMITED
    Inventors: Alan Geoffrey Roach, Paul Goldsmith
  • Publication number: 20100113570
    Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.
    Type: Application
    Filed: April 23, 2009
    Publication date: May 6, 2010
    Applicants: The General Hospital Corporation, D/B/A MASSACHUSETTS GENERAL HISPITAL
    Inventors: Zhongcong Xie, Rudolph E. Tanzi
  • Patent number: 7695635
    Abstract: An azeotropic or azeotrope-like composition comprising a mixture of methyl iodide, 1-chloro-3,3,3,-trifluoropropene, and optionally one or more of fluorocarbons and/or hydrofluorocarbons. The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: April 13, 2010
    Assignee: Honeywell International Inc
    Inventors: Rajiv R. Singh, Hang T. Pham, Andrew J. Poss
  • Patent number: 7687455
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: March 30, 2010
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 7572798
    Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: August 11, 2009
    Assignee: McGill University
    Inventors: Bertrand J. Jean-Claude, Fabienne Dudouit, Stephanie Matheson
  • Patent number: 7572782
    Abstract: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively stimulate bone regeneration and increase osteoblastic activity in a patient.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: August 11, 2009
    Assignee: Torquin, LLC
    Inventor: Robert F. Hofmann
  • Patent number: 7544306
    Abstract: Azeotropic and azeotrope-like compositions of methyl iodide and at least one fluorocarbon or hydrofluorocarbon such as 1,1,1,3,3-pentafluoropropane (HFC-245fa). The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: June 9, 2009
    Assignee: Honeywell International Inc.
    Inventors: Andrew J. Poss, Rajiv R. Singh, Hang T. Pham
  • Publication number: 20090060905
    Abstract: The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.
    Type: Application
    Filed: July 30, 2008
    Publication date: March 5, 2009
    Applicant: Genfit
    Inventors: Genevieve Martin, Sebastien Barradeau, Sakina Sayah-Jeanne
  • Patent number: 7488854
    Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 10, 2009
    Assignees: The National Institute of Agrobiological Sciences, Riken
    Inventors: Shigemi Seo, Yuko Ohashi, Hideharu Seto, Shigeo Yoshida
  • Publication number: 20090018215
    Abstract: The present invention provides a fumigant for wood parasitic nematodes comprising methyl iodide dissolved in liquefied carbon dioxide, in place of methyl bromide the use of which is globally regulated as ozone depleting substance or a fumigant using methyl iodide dissolved in liquefied carbon dioxide in combination with one or more compounds selected from the group consisting of sulfuryl fluoride, methyl isothiocyanate, phosphine, ethylene oxide, carbonyl sulfide and propylene oxide, and a fumigation method for killing wood parasitic nematodes by using said fumigant.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 15, 2009
    Applicants: Yashima Sangyo Co., LTD., Japan Fumigation Technology Association, Arysta Life Science Corporation
    Inventors: Yutaka Abe, Yoshio Hisada, Toru Itabashi, Hiroyuki Miyaji, Yukihiro Soma, Yasuo Matsumoto, Hitoshi Komatsu
  • Publication number: 20080268067
    Abstract: This invention relates to methods of inhibiting a Cav3 calcium channel in a cell using a C2-C10 alkyl alcohol, or mixtures thereof. This invention further relates to methods of treating a thalamocortical dysrhythmia disorder in a mammal and for treating a neurological disorder in a mammal associated with the thalamocortical dysrhythmia using a C2-C10 alkyl alcohol, a lipophilic molecule with a partition coefficient substantially similar to that of a C2-C10 alkyl alcohol, or mixtures thereof, or a pharmaceutical composition comprising the same.
    Type: Application
    Filed: March 10, 2008
    Publication date: October 30, 2008
    Inventors: Rodolfo R. Llinas, Mutsuyuki Sugimori, Francisco Urbano
  • Publication number: 20080234322
    Abstract: Drug delivery models, displays, and systems may be configured to provide a clinician with readily intuitive information about the effects of one or more drugs on a subject. Interactive features may be included to provide a subject-specific model of the expected or predicted effects of one or more drugs on the subject. Additionally, interactive features that effect drug delivery to the subject may also be included. Drug delivery models, displays, and systems may be used in teaching, in advance of treatment, during treatment, or following treatment.
    Type: Application
    Filed: March 20, 2007
    Publication date: September 25, 2008
    Inventors: Noah Syroid, Dwayne R. Westenskow, James Agutter, Talmage D. Egan, Kenward B. Johnson
  • Publication number: 20080145390
    Abstract: Method and article for providing a rapid, broad spectrum bacterial control, and a rapid and persistent antiviral control on an inanimate surface is disclosed. In the method, a compound or composition capable of lowering surface pH to less than about 4 is applied to the surface, and preferably is allowed to remain on the surface, and the nonvolatile components of the composition can form a barrier film or layer on a treated surface.
    Type: Application
    Filed: June 4, 2007
    Publication date: June 19, 2008
    Applicant: THE DIAL CORPORATION
    Inventors: Timothy J. Taylor, Harry E. Towner, Janice L. Fuls, Bruce R. Cox, George E. Fischler, Priscilla S. Fox, Nancy D. Rodgers, James Dalton, Daniel E. Pedersen, John J. Rolando, Richard K. Staub
  • Patent number: 7378449
    Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: May 27, 2008
    Assignee: Albemarle Corporation
    Inventors: Raymond B. Dawson, Saadat Hussain
  • Patent number: 7220784
    Abstract: The present invention relates to stilbene and quinone compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BOC amino acid esters are formed with the phenolic hydroxyl at the 3-position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior art stilbenes.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 22, 2007
    Inventors: John Anthony Hadfield, Alan Thomson McGown, Stephen Patrick Mayalarp, Edward John Land, Ian Hamblett, Keira Gaukroger, Nicholas James Lawrence, Lucy Annette Hepworth, John Butler
  • Patent number: 7074434
    Abstract: Process for the separation of a mixture comprising at least one hydrofluoroalkane and hydrogen fluoride, according to which a hydrofluoroalkane/hydrogen fluoride mixture is reacted with at least one chlorinated or chlorofluorinated precursor of the hydrofluoroalkane. Process for the preparation of a hydrofluoroalkane comprising such a separation, in combination with a catalytic reaction stage. Azeotropic compositions.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: July 11, 2006
    Assignee: Solvay (Societe Anonyme)
    Inventors: Alain Lambert, Vincent Wilmet
  • Patent number: 7026359
    Abstract: The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—RF(CH2)nCR1—CR2—]x, wherein RF is a linear or branched perfluorinated alkyl chain C2F5 to C12F23, R1 and R2 are independently selected from the group consisting of H, CH3, C2H5 and C3H7, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: April 11, 2006
    Assignee: Bausch & Lomb Incorporated
    Inventors: Udo Gross, Dirk-Henning Menz, Erhard Kemnitz, Hans Hoerauf, Karin Kobuch
  • Patent number: 6927237
    Abstract: The present invention relates to two solvent antimicrobial compositions and methods employing these two solvent compositions. The two solvent compositions typically contain a second solvent that is not or is only sparingly soluble in a diluting solvent. The two solvent composition can form a clear single-phase solution. The two solvent antimicrobial compositions can reduce the population of microbes on various surfaces such as facilities, containers, or equipment found in food, beverage, or pharmaceutical industries at temperatures between about ?70° C. to about 100° C.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: August 9, 2005
    Assignee: Ecolab Inc.
    Inventors: Robert D. P. Hei, Brandon Herdt, Lawrence Grab
  • Patent number: 6884797
    Abstract: Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: April 26, 2005
    Inventor: Robert F. Hofmann
  • Patent number: 6861451
    Abstract: Carboxylic acid fluorides having a boiling point of preferably less than 100° C. are suitable for use as pesticides. Acetyl fluoride is highly suitable, and Chlorodifluoroacetyl fluoride and trifluoroacetyl fluoride are also very useful. Mixtures of carboxylic acid fluoride pesticides and other pesticides are also disclosed.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: March 1, 2005
    Assignee: Solvay Fluor und Derivate GmbH
    Inventors: Max Braun, Francine Janssens, Reiner Fischer
  • Publication number: 20040259816
    Abstract: Disclosed are methods for treating, preventing, or inhibiting diseases and disorders associated with NF-&kgr;B activation including proliferative diseases such as cancer and inflammatory diseases such as pancreatitis in a subject which comprises administering at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species to the subject. Also disclosed are pharmaceutical compositions comprising at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.
    Type: Application
    Filed: April 15, 2004
    Publication date: December 23, 2004
    Inventors: Stephen J. Pandol, Anna Gukovskaya, Moussa Yazbeck, Guido Eibl, Laszlo G. Boros
  • Publication number: 20040127578
    Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.
    Type: Application
    Filed: October 9, 2003
    Publication date: July 1, 2004
    Applicant: Baxter International Inc.
    Inventors: Raul Trillo, Ralph A. Lessor, Satish Pejaver, Navneet Puri
  • Publication number: 20040120926
    Abstract: Compositions and methods for treating a variety of conditions in which a reactive oxygen metabolite (ROM) inhibitor or scavenger is administered alone or in conjunction with additional agents. Such conditions include, cancer, viral diseases, and inflammatory diseases, for example.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 24, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6743825
    Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: June 1, 2004
    Assignee: Albemarle Corporation
    Inventors: Raymond B. Dawson, Saadat Hussain
  • Patent number: 6528545
    Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formula RF1—W—RH1  (I) wherein RF1 is a linear, branched or cyclic C2-14 fluorocarbon group; RH1 is a linear, branched or cyclic C2-18 saturated or unsaturated hydrocarbon group; and W is absent or is a bivalent species chosen from the group consisting of —O—, —S—, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: March 4, 2003
    Inventors: Jean G. Riess, Michele Postel, Luis Sole-Violan, Marie-Pierre Krafft, Chantal Cornelus
  • Publication number: 20020198266
    Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.
    Type: Application
    Filed: May 15, 2001
    Publication date: December 26, 2002
    Inventor: Hasso Meinert
  • Patent number: 6465527
    Abstract: Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds by applying a compound comprised of both mono-iodinated hydrocarbons and di-iodinated hydrocarbons. The combination provides an effective insecticide and nemacide along with herbicidal properties without causing significant harm to the ozone layer. Additionally disclosed is a method of soil fumigation comprising applying to a soil an effective amount of a fumigant selected from diiodinated hydrocarbons, polyiodinated hydrocarbons and their combinations.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 15, 2002
    Assignee: Auburn University
    Inventors: Rodrigo Rodriguez-Kabana, Arthur G. Appel
  • Patent number: 6420436
    Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: July 16, 2002
    Assignee: Alliance Pharmaceutical Corp.
    Inventor: W. Dean Kirkland
  • Publication number: 20020068767
    Abstract: A container for liquid inhalation anesthetics, more particularly, an aluminum container that is suitable for storing halogenated inhalation anesthetics is described.
    Type: Application
    Filed: September 13, 2001
    Publication date: June 6, 2002
    Inventors: Ralph V. Rudzinski, Ralph A. Lessor
  • Publication number: 20020068765
    Abstract: This invention describes the new benzocycloheptenes of general formula I 1
    Type: Application
    Filed: July 19, 1999
    Publication date: June 6, 2002
    Inventors: ROLF BOHLMANN, JORG KROLL, HERMANN KUENZER, CHRISTA HEGELE-HARTUNG, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO
  • Publication number: 20020010218
    Abstract: A breathing gas mixture is provided for the treatment of lung diseases, containing an amount of perfluorocarbon and oxygen containing 5 vol. % to 40 vol. % of perfluorocarbon relative to the amount of perfluorocarbon and oxygen. The amount of perfluorocarbon and oxygen in the breathing gas mixture ranges from about 20 vol. % to a maximum of 100 vol. % of the breathing gas mixture, and the remaining amount of up to about 80 vol. % contains one or more of the gases nitrogen, nitrogen monoxide and/or one or more anesthesia gases or noble gases, especially xenon. Perfluorohexane is an especially preferred perfluorocarbon.
    Type: Application
    Filed: July 24, 2001
    Publication date: January 24, 2002
    Inventor: Detlev Michael Albrecht
  • Publication number: 20010031740
    Abstract: The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired.
    Type: Application
    Filed: December 21, 2000
    Publication date: October 18, 2001
    Applicant: ImaRX Pharmaceutical Corporation
    Inventors: Evan C. Unger, Thomas McCreery